

Assessing Long-term Outcomes of Dupilumab (AROMA): Real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps

AROMA registry (NCT04959448)

Screening

- Recruitment target of 1000 dupilumab-naïve adult patients with severe CRSwNP

Baseline


- Initiation of dupilumab and assessment of real-world demographics, disease characteristics, coexisting conditions, and treatment history

Study period

- Scheduled visits every 3 months to Month 24 then every 6 months to Month 36

120 study sites in 7 countries:

USA, Canada, France, Germany, Italy, Netherlands, Japan



Endpoints

Primary

- Objective disease measures assessed as part of routine clinical care
- Patient-reported outcomes

Secondary

- Concomitant medications
- Adverse events

Exploratory

- Steroid use
- Requirement for surgery
- Controller medication use in patients with coexisting asthma

Conclusion

- The AROMA registry will prospectively characterise the effectiveness of dupilumab in a real-world setting